$FTLF
FITLIFE BRANDS, INC.

2023 Q1 Form 10-K Financial Statement

#000143774923007858 Filed on March 24, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $10.74M $5.370M $28.80M
YoY Change 44.04% -22.16% 3.23%
Cost Of Revenue $6.330M $3.182M $16.77M
YoY Change 51.33% -20.21% 8.83%
Gross Profit $4.408M $2.188M $12.03M
YoY Change 34.72% -24.84% -3.68%
Gross Profit Margin 41.05% 40.74% 41.78%
Selling, General & Admin $2.344M $1.390M $6.267M
YoY Change 41.03% -10.9% 0.84%
% of Gross Profit 53.18% 63.53% 52.08%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $19.00K $17.00K $66.00K
YoY Change 35.71% -5.56% 11.86%
% of Gross Profit 0.43% 0.78% 0.55%
Operating Expenses $3.735M $1.407M $6.333M
YoY Change 122.85% -10.84% 0.94%
Operating Profit $673.0K $781.0K $5.701M
YoY Change -57.83% -41.41% -8.34%
Interest Expense $98.00K $62.00K $121.0K
YoY Change 1300.0% 785.71% 384.0%
% of Operating Profit 14.56% 7.94% 2.12%
Other Income/Expense, Net -$96.00K $121.0K
YoY Change -1471.43% -74.69%
Pretax Income $577.0K $800.0K $5.822M
YoY Change -64.0% -40.3% -13.08%
Income Tax $421.0K $327.0K $1.393M
% Of Pretax Income 72.96% 40.88% 23.93%
Net Earnings $156.0K $473.0K $4.429M
YoY Change -87.91% -55.04% -17.51%
Net Earnings / Revenue 1.45% 8.81% 15.38%
Basic Earnings Per Share $0.03 $0.97
Diluted Earnings Per Share $0.03 $0.10 $0.89
COMMON SHARES
Basic Shares Outstanding 4.446M 4.556M 4.553M
Diluted Shares Outstanding 4.935M 4.975M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.977M $13.28M $13.28M
YoY Change -27.88% 34.15% 34.15%
Cash & Equivalents $8.927M $13.28M
Short-Term Investments
Other Short-Term Assets $2.397M $116.0K $116.0K
YoY Change 1352.73% -60.68% -60.68%
Inventory $8.791M $9.105M $9.105M
Prepaid Expenses
Receivables $2.045M $705.0K $705.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $21.21M $23.20M $23.20M
YoY Change 6.0% 31.41% 31.41%
LONG-TERM ASSETS
Property, Plant & Equipment $118.0K $46.00K $149.0K
YoY Change 100.0% -79.82% -34.65%
Goodwill $10.79M $358.0K
YoY Change 2913.13% 0.0%
Intangibles $7.769M $150.0K
YoY Change 4192.27% -21.88%
Long-Term Investments
YoY Change
Other Assets $1.596M $1.847M $1.847M
YoY Change -41.67% -39.34% -39.34%
Total Long-Term Assets $20.46M $2.504M $2.504M
YoY Change 486.94% -34.5% -34.5%
TOTAL ASSETS
Total Short-Term Assets $21.21M $23.20M $23.20M
Total Long-Term Assets $20.46M $2.504M $2.504M
Total Assets $41.67M $25.71M $25.71M
YoY Change 77.34% 19.68% 19.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.881M $2.995M $2.995M
YoY Change 43.1% 3.99% 3.99%
Accrued Expenses $1.987M $685.0K $685.0K
YoY Change 250.44% 18.31% 18.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.500M $0.00
YoY Change
Total Short-Term Liabilities $9.949M $4.270M $4.270M
YoY Change 114.79% 4.38% 4.38%
LONG-TERM LIABILITIES
Long-Term Debt $10.00M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $108.0K $49.00K $49.00K
YoY Change 20.0% -52.43% -52.43%
Total Long-Term Liabilities $10.00M $49.00K $49.00K
YoY Change 11011.11% -52.43% -52.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.949M $4.270M $4.270M
Total Long-Term Liabilities $10.00M $49.00K $49.00K
Total Liabilities $20.06M $4.319M $4.319M
YoY Change 324.76% 2.98% 2.98%
SHAREHOLDERS EQUITY
Retained Earnings -$8.557M -$8.713M
YoY Change -27.8% -33.7%
Common Stock $44.00K $45.00K
YoY Change -4.35% -2.17%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00
YoY Change -100.0%
Treasury Stock Shares $0.00
Shareholders Equity $21.61M $21.39M $21.39M
YoY Change
Total Liabilities & Shareholders Equity $41.67M $25.71M $25.71M
YoY Change 77.34% 19.68% 19.68%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $156.0K $473.0K $4.429M
YoY Change -87.91% -55.04% -17.51%
Depreciation, Depletion And Amortization $19.00K $17.00K $66.00K
YoY Change 35.71% -5.56% 11.86%
Cash From Operating Activities $232.0K -$873.0K $4.130M
YoY Change -79.54% -168.2% -7.81%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$17.10M $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$17.10M $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $779.0K
YoY Change -299.74%
Debt Paid & Issued, Net $0.00 $0.00
YoY Change
Cash From Financing Activities $12.50M -779.0K -$750.0K
YoY Change 43003.45% 92.31%
NET CHANGE
Cash From Operating Activities $232.0K -873.0K $4.130M
Cash From Investing Activities -$17.10M 0.000 $0.00
Cash From Financing Activities $12.50M -779.0K -$750.0K
Net Change In Cash -$4.350M -1.652M $3.380M
YoY Change -474.03% -229.06% -5.08%
FREE CASH FLOW
Cash From Operating Activities $232.0K -$873.0K $4.130M
Capital Expenditures $0.00 $0.00
Free Cash Flow $232.0K $4.130M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
50000 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
55000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
107000 usd
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
56000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
72000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
30000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4507361
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4507361
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4552485
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4552485
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
881311
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
143480
CY2021 ftlf Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
CY2021 ftlf Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
0
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
143480
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2022 us-gaap Open Tax Year
OpenTaxYear
2018 2019 2020 2021 2022
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-52369
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3464383
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
5214 S. 136th Street
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Omaha
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NE
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
68137
CY2022 dei City Area Code
CityAreaCode
402
CY2022 dei Local Phone Number
LocalPhoneNumber
991-5618
CY2022 dei Security12g Title
Security12gTitle
Common Stock, $0.01 par value per share
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
21079000 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4446161
CY2022 dei Auditor Firm
AuditorFirmId
572
CY2021 dei Auditor Firm
AuditorFirmId
410
CY2022 dei Auditor Name
AuditorName
Weinberg & Company, P.A.
CY2022 dei Auditor Location
AuditorLocation
Los Angeles, California
CY2021 dei Auditor Name
AuditorName
WEAVER AND TIDWELL, L.L.P.
CY2021 dei Auditor Location
AuditorLocation
Fort Worth, Texas
CY2022Q4 us-gaap Cash
Cash
13277000 usd
CY2021Q4 us-gaap Cash
Cash
9897000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
705000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
945000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9105000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
6520000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
116000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
322000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
23203000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
17684000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
103000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
158000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
150000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
192000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
358000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
358000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1847000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3045000 usd
CY2022Q4 us-gaap Assets
Assets
25707000 usd
CY2021Q4 us-gaap Assets
Assets
21507000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2995000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2880000 usd
CY2022Q4 ftlf Accrued Expense And Other Liabilities Current
AccruedExpenseAndOtherLiabilitiesCurrent
631000 usd
CY2021Q4 ftlf Accrued Expense And Other Liabilities Current
AccruedExpenseAndOtherLiabilitiesCurrent
491000 usd
CY2022Q4 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
590000 usd
CY2021Q4 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
632000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
55000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4270000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4058000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
103000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4319000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
4161000 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
45000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
46000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
-0 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2087000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
30056000 usd
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
92000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32529000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8713000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13142000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21388000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
17346000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25707000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21507000 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
28803000 usd
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
27913000 usd
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16769000 usd
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15409000 usd
CY2022 us-gaap Gross Profit
GrossProfit
12034000 usd
CY2021 us-gaap Gross Profit
GrossProfit
12504000 usd
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6267000 usd
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6215000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
66000 usd
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
59000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
6333000 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
6274000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
5701000 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
6230000 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
121000 usd
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
25000 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
453000 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
121000 usd
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
478000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5822000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6708000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1393000 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1298000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
4429000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
5410000 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.97
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.23
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.89
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.13
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4552533
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4406614
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4974596
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4801370
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
17346000 usd
CY2022 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
772000 usd
CY2022 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
7000 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
363000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
4429000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21388000 usd
CY2021 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
260000 usd
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54000 usd
CY2021 ftlf Adjustments To Additional Paid In Capital Repurchase Of Options
AdjustmentsToAdditionalPaidInCapitalRepurchaseOfOptions
184000 usd
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
452000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
5410000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
4429000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
5410000 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
66000 usd
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
59000 usd
CY2022 ftlf Operating Lease Rightofuse Asset Net Of Amortization And Lease Liability
OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability
-55000 usd
CY2021 ftlf Operating Lease Rightofuse Asset Net Of Amortization And Lease Liability
OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability
-50000 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-6000 usd
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4000 usd
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
51000 usd
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
0 usd
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
363000 usd
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
452000 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
453000 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-247000 usd
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-974000 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2636000 usd
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2945000 usd
CY2022 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-1199000 usd
CY2021 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-1294000 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-204000 usd
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
270000 usd
CY2022 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-0 usd
CY2021 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-40000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
115000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-366000 usd
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-55000 usd
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-50000 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
140000 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6000 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-42000 usd
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
287000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4130000 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4480000 usd
CY2022 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
-0 usd
CY2021 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
529000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-529000 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000 usd
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
54000 usd
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
779000 usd
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
444000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-750000 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-390000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3380000 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3561000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9897000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6336000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13277000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9897000 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3000 usd
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-42000 usd
CY2022 us-gaap Notes Reduction
NotesReduction
0 usd
CY2021 us-gaap Notes Reduction
NotesReduction
453000 usd
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">1.</em></b>  <b>DESCRIPTION OF BUSINESS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">FitLife Brands, Inc. (the “<i>Company</i>”) is a national provider of innovative and proprietary nutritional supplements for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, and Metis Nutrition (together, “<i>NDS Products</i>”); and (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "<i>iSatori Products</i>"). The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“<i>GNC</i>”) stores located both domestically and internationally, and, with the launch of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through more than 17,000 retail locations, which include specialty, mass, and online.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s Common Stock, par value $0.01 per share (“<i>Common Stock</i>”), trades under the symbol “FTLF” on the OTC Pink market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Developments</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Forward Stock Split</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Board of Directors of the Company (the “<i>Board</i>”) approved a forward stock split of the Company’s authorized, issued and outstanding shares of common stock, par value $0.01 per share (the “<i>Common Stock</i>”), at a ratio of 4-for-<em style="font: inherit;">1</em> (the “<i>Forward Split</i>”). The Forward Split was effective as of <em style="font: inherit;"> December 2, 2021 </em>and began trading on such basis on <em style="font: inherit;"> December 8, 2021. </em>Prior to the Forward Split, the Company was authorized to issue 15.0 million shares of Common Stock. As a result of the Forward Split, the Company is now authorized to issue 60.0 million shares of Common Stock. The Forward Split did have any effect on the stated par value of the Common Stock and did <em style="font: inherit;">not</em> affect the Company’s authorized preferred stock.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">All references in this Annual Report to number of common shares, price per share and weighted average number of shares outstanding have been adjusted to reflect the Forward Split on a retroactive basis as of the earliest period presented, unless otherwise noted.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>COVID-<em style="font: inherit;">19</em> Pandemic</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The COVID-<em style="font: inherit;">19</em> pandemic has had an effect on the Company’s employees, business and operations and those of its customers, vendors and business partners. In this respect, the temporary or permanent closure of some of our retail partners’ store locations and the stay-at-home orders that occurred early in the pandemic negatively affected our results from operations, although much of the impact has been offset by an increase in revenue attributable to online sales, and increased sales during the more recent quarters. Our future financial position and operating results could be materially and adversely affected in the event that a resurgence of COVID-<em style="font: inherit;">19</em> cases leads to new stay-at-home orders and/or further disruptions in both our supply chain and manufacturing lead-times, which could lower demand for the Company’s products and/or prevent the Company from producing and delivering its products in a timely manner, although the extent of these effects cannot be determined at this time. The Company expects to continue to assess the evolving impact of the COVID-<em style="font: inherit;">19</em> pandemic and intends to make adjustments to its business and operations accordingly. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Inflation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has experienced inflationary pressure with regard to the procurement of many of its products.  Thus far, the Company has been able to partially offset the impact of inflation through price increases to its customers.  In the future, however, further inflationary pressure could adversely affect the Company’s operating performance if market conditions <em style="font: inherit;">no</em> longer permit the Company to pass through price increases to its customers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
4 pure
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
15000000.0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000.0
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Use of Estimates and Assumptions</span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“<i>GAAP</i>”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, depreciable lives of property and equipment, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><span style="text-decoration: underline; ">Customer Concentration</span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Total net sales to GNC during <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> were 67 % and 71% of total revenue for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively. Accounts receivable attributable to GNC as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> represented 43% and 85% of the Company’s total accounts receivable balance, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
50000 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
55000 usd
CY2022Q4 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
590000 usd
CY2021Q4 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
632000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
107000 usd
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
56000 usd
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
4552533
CY2021 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
4406614
CY2022 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
422063
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
394756
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4974596
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4801370
CY2021Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
48000 usd
CY2021Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
126000 usd
CY2021Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
222000 usd
CY2021Q2 us-gaap Goodwill
Goodwill
133000 usd
CY2021Q2 ftlf Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets Including Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill
529000 usd
CY2021Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
222000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8347000 usd
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5908000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
865000 usd
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
668000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
107000 usd
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
56000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9105000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
6520000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
902000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
902000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
856000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
832000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70000 usd
CY2022 us-gaap Depreciation
Depreciation
24000 usd
CY2021 us-gaap Depreciation
Depreciation
28000 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
100000 usd
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09 pure
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09 pure
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
103000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
158000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
55000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
103000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
103000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
158000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
61000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
51000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
103000 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
18 usd
CY2021Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
4 pure
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
15000000.0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000.0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4507361
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4552485
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021 ftlf Sharebased Compensation Arrangement By Sharebased Payment Award Options Repurchased
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRepurchased
50840
CY2021 ftlf Payments For Repurchase Of Options
PaymentsForRepurchaseOfOptions
184000 usd
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
371140
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.51
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
128000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.03
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
68000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.48
CY2021 ftlf Sharebased Compensation Arrangement By Sharebased Payment Award Options Repurchased
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRepurchased
50840
CY2021 ftlf Sharebased Compensation Arrangement By Sharebased Payment Award Options Repurchased Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRepurchasedWeightedAverageExercisePrice
3.48
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
380300
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.44
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
10000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.65
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3472
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.27
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7336
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
35.88
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
379492
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.09
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M18D
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
379492
CY2022 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y3M18D
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.09
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
307992
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.38
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4930000 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
10000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.65
CY2022 ftlf Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue
89000 usd
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
128000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.03
CY2021 ftlf Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue
185000 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76000 usd
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
160000 usd
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
146000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
143480
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2124000 usd
CY2022 ftlf Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
CY2022 ftlf Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
0
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.15
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1393000 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1298000 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
199000 usd
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
14000 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1194000 usd
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1284000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1393000 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1298000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2034000 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3209000 usd
CY2022Q4 ftlf Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns Bad Debt And Inventory
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsBadDebtAndInventory
157000 usd
CY2021Q4 ftlf Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns Bad Debt And Inventory
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsBadDebtAndInventory
155000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
88000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
16000 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
105000 usd
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
202000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2384000 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3582000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
537000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
537000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1847000 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3045000 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.03 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0 pure
CY2022 ftlf Effective Income Tax Rate Reconciliation Federal And State Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationFederalAndStateStatutoryIncomeTaxRate
0.24 pure
CY2021 ftlf Effective Income Tax Rate Reconciliation Federal And State Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationFederalAndStateStatutoryIncomeTaxRate
0.21 pure
CY2022 ftlf Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0 pure
CY2021 ftlf Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.07 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.24 pure
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.14 pure

Files In Submission

Name View Source Status
ftlf-20221231_cal.xml Edgar Link unprocessable
0001437749-23-007858-index-headers.html Edgar Link pending
0001437749-23-007858-index.html Edgar Link pending
0001437749-23-007858.txt Edgar Link pending
0001437749-23-007858-xbrl.zip Edgar Link pending
ex_477820.htm Edgar Link pending
ex_477821.htm Edgar Link pending
ex_477822.htm Edgar Link pending
ex_477823.htm Edgar Link pending
ex_492814.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ftlf-20221231.xsd Edgar Link pending
ftlf20221231_10k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
ftlf-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ftlf-20221231_def.xml Edgar Link unprocessable
ftlf-20221231_pre.xml Edgar Link unprocessable
ftlf20221231_10k_htm.xml Edgar Link completed
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending